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SUMMARY – Ginkgo biloba L. is the eldest plant growing on the Earth; preparations made of its 
leaves and seeds represent an integral part of the Chinese medicine for over a millennium. The plant 
species was first discovered by Linnaeus in 1771, its name thereby originating from the Latin words 
bis (two) and lobus (lobe), which duly illustrate the specific shape of its leaf. Contemporary Ginkgo 
biloba L. plant based pharmaceuticals mostly comprise extracts recovered from leaves harvested during 
fall, when the concentration of active components reaches its peak. Recent investigations have man-
aged to establish the chemical composition of the plant leaf, together with the mechanisms underlying 
its beneficial effects on rheological profile of the blood and acceleration of its flow. High price of these 
preparations and their vast popularity have soon become an incentive for counterfeiting Ginkgo biloba 
L. extracts and the release of bogus drugs comprising cheaper extracts coming from other plants. 
Namely, modern Ginkgo biloba L.-based medicinal products and food supplements comprise extracts 
recovered from the plant leaf that get to be standardized according to its key pharmacological active 
components, most often flavone glycosides (represented in the share of 22%-27%) and terpene trilac-
tones (represented in the share of 6%-7%). The flavonoids that predominate such preparations and are 
most relevant from the pharmacological standpoint are quercetin, kaempferol and isorhamnetin, their 
total amount and mutual ratios, thereby being an unquestionable indicator of the extract authenticity. 
Therefore, most of the analyses aiming at verifying the authenticity of a given Ginkgo biloba L.-based 
product boil down to the analysis of these parameters. Counterfeiting involves partial or full replace-
ment of the Ginkgo biloba L. extract (GBE) with a cheaper plant extract of a similar composition, the 
latter occasionally being enriched with an additional amount of flavonoids, most often quercetin, not 
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originating from the Ginkgo biloba L. plant. The aim of this study was to verify the authenticity and 
quality of Ginkgo biloba L.-based products circulating on the Croatian market. To that effect, 10 
samples of products produced by various manufacturers were analyzed in a certified laboratory. The 
parameters based on which the authenticity of the preparations was assessed were the shares of agly-
cones of typical ginkgo flavone glycosides, that is to say, quercetin, kaempferol and isorhamnetin, and 
mutual ratios of the established quantities of quercetin to kaempferol as the key clues to unmasking 
Ginkgo extracts counterfeiting. The amount of ginkgo flavone glycosides was established using high 
performance liquid chromatography. The analysis proved 80% of the samples analyzed to be confor-
mant to the label statements as regards the total amount of flavone glycosides and their mutual ratios. 
In 20% of the samples, the ratio of quercetin to kaempferol deviated from normal values; on top of 
that, the presence of the phytoestrogen genistein, one of the components typically comprised by the 
Sophora japonica L. plant, was also proven, documenting counterfeiting of the GBE and its replace-
ment by the Sophora japonica L. extracts in the samples under consideration. Due to the untrue label 
statements descriptive of these products, the information on the presence of pharmacologically active 
genistein was neglected to be mentioned despite its unfavorable health impact that can be expected in 
some consumer groups. The results of this study indicated the frequency of counterfeiting the Ginkgo 
biloba L.-based products found on the Croatian market to be deemed substantial. Therefore, a more 
rigorous and more thorough control of these products and sanctioning of irresponsible manufacturers 
and distributers is proposed, so as to contribute to a higher market representation of high-quality 
products, as well as to avoid health risks and downsize the rate of their counterfeiting.
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Introduction
Ginkgo biloba L. (family: Ginkgoaceae; class: Gink-
goatae) is the eldest plant growing on the planet Earth, 
its origin dating 250-260 million years back into the 
history of our planet1. Given that it does not show any 
botanical or taxonomic kindredness with other plant 
species currently inhabiting our planet, it is called a 
living fossil plant. The plant is grown virtually all over 
the world. The eldest data on therapeutic virtues of the 
Ginkgo biloba L. and its medicinal use can be found in 
the roughly 5000-year old Chinese Pharmacopeia. The 
plant represents an integral part and a common ‘tool’ 
of the traditional Chinese medicine that has been used 
throughout its history, in particular to the effect of al-
leviating asthma symptoms and cough, and to cure 
bronchitis and impotence.
Current analytical techniques have managed to es-
tablish chemical composition of the Ginkgo biloba L. 
plant and uncover some of the mechanisms underlying 
its impact on rheological profile of the blood and en-
hancement of its flow. These discoveries have contrib-
uted to an ever-growing use of the plant to the effect 
of health preservation and alleviation of various symp-
toms. The production of Ginkgo biloba L.-based prepa-
rations witnessed its rise following 1994, when the 
World Health Organization (WHO) and Federal 
Commission for Drug Monographs of the Federal 
Republic of Germany (E Commission) released a 
Ginkgo biloba L. extract (GBE) devoted monograph 
bringing a positive review on it, which was taken as 
formal approval of the plant administration to the end 
of enhancing peripheral and cerebral blood flow1-3.
Among roughly 50 compounds isolated from the 
plant insofar, those most relevant for its biological ac-
tivity are the following two groups of substances: fla-
vonoids and terpene trilactones4. The composition of 
the plant is predominated by flavonoids, among which 
the most represented are flavonol mono-, di- and tri-
glycosides having an ester bond with the p-coumarin 
acid5. Aglyconic molecular parts of typical ginkgo fla-
vone glycosides are quercetin, kaempferol and isorh-
amnetin6.
The terpene trilactone group, a unique component 
comprised by the Ginkgo biloba L. only, is represented 
by diterpene lactone ginkgolides A, B, C, J and M, and 
sesquiterpene lactone bilobalide7.
In nature, these unique compounds can be found 
solely in the Ginkgo biloba L. plant. Clinical trials have 
shown the administration of GBE to be justified as ad-
juvant therapy in a number of conditions including 
blood flow impairments8, impotence, migraine9, vitili-
go10, cardiac symptoms, eye impairments, neurasthenic 
complaints11, tinnitus12, chronic cerebral insufficiency13, 
forgetfulness14, depression, dementia15,16 and senile con-
ditions17, blood preasure18 and Alzheimer’s disease19.
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Therapeutic effects of this plant are attributed to 
the synergistic activity of all plant components. Still, 
certain acting mechanisms are attributed to particular 
groups of compounds; for instance, when it comes to 
the exchange of substances through vessel walls and 
vessel wall fragility, the most often tagged substances 
are ginkgo flavone glycosides20. On top of the above-
mentioned effects, these compounds manifest a high 
antioxidative activity because of which the Ginkgo bi-
loba L. plant has a high capacity of binding free radi-
cals21,22.
Owing to binding and deactivation of oxygen radi-
cals rich in energy, the plant also increases tissue toler-
ance to the lack of oxygen. It is also believed that some 
differences exist in the acting mechanisms of individu-
al flavone derivatives. For instance, quercetin has a 
more profound impact on low-density lipoprotein 
(LDL)-cholesterol reduction23; on top of that, it ex-
hibits vasodilating and antiviral effects24, and has been 
proven to act as an antihistamine drug25.
Kaempferol aids in the prevention of atherosclerosis 
owing to the inhibition of LDLs. It also inhibits platelet 
aggregation and development of malignant cells26.
Terpene trilactones are believed to be capable of 
inhibiting the platelet activation factor (PAF) that in-
duces platelet aggregation, as well as the development 
of edemas, smooth muscle contractions, hypertension, 
bronchial constriction, increased microvascular per-
meability, increased hematocrit and lysosomal enzyme 
secretion27,28.
Notwithstanding its favorable characteristics, at-
tention should also be paid to the adverse effects of 
Ginkgo biloba L. in terms of its interactions with drugs 
of the anticoagulant class, as well as with other drugs 
preventing platelet aggregation, making the concomi-
tant use of the two contraindicated. Of note, ginkgolic 
acid can also exhibit harmful effects, so its concentra-
tion in a standardized extract should not go beyond 5 
mg/kg29.
An incentive for designing a vast number of Ginkgo 
biloba L.-based food supplements was a marked bio-
logical activity related to the plant. Therefore, the plant 
can be found in such products in various shares. GBE 
has grown to become an integral part of herbal me-
dicinal products, food supplements, cosmetic and bor-
derline (cosmetic/medicinal) products30.
In order to achieve the expected biological activity, 
it is absolutely essential for a product to have a well-
balanced, natural and reliable composition of extracts; 
in the light of the foregoing, the rise in the demand for 
GBE-based products has made GBE standardization 
imperative. A standardized dry GBE is obtained by 
virtue of extraction from the ginkgo leaf using a sol-
vent (acetone and water). In the subsequent course, the 
extract should be cleansed of not only solvent, but also 
of the ginkgolic acid that may induce an allergic re-
sponse, let alone toxic effects should it be present in 
higher quantities. Standardization of purified GBE 
most often aims at 24% representation of ginkgo fla-
vone glycosides and 6% representation of terpene lac-
tones31. Specifications stated by the manufacturer of a 
standardized GBE should reveal the percent-shares of 
the above substances, with the same piece of informa-
tion advertised on the product label.
Verification of genuineness and quality of GBE and 
GBE-based products relies on the analysis of GBE key 
components falling into the groups of flavonoids and 
terpene trilactones.
High demand, high price and an ever-growing 
supply have unanimously affected the frequency of 
counterfeiting that involves either partial or full re-
placement of GBE with a cheaper plant extract similar 
in composition. In order to harmonize the total 
amount of ginkgo flavone glycosides comprised by 
counterfeit drugs with the GBE standards and labeled 
values, the extract gets to be enriched by an additional 
amount of flavonoids not coming from the Ginkgo bi-
loba L. plant. To the above effect, quercetin, i.e. its gly-
coside form rutin, is exploited. The latter represents 
one of the most common flavonoids that, among other, 
can be isolated from buckwheat (Fagopyrum esculentum 
Moench), elder flower (Sambucus nigra L.), herb-of-
grace (Ruta graveolens L.), citruses and other plants, 
fruit and vegetables32-34.
By virtue of these interventions, the total amount 
of flavone glycosides present in fake drugs and the 
amount present in an original GBE are usually equal-
ized but their mutual ratios, which, besides their per-
cent-shares, pose as the key criteria guiding the verifi-
cation of GBE genuineness or counterfeiting disclo-
sure, witness changes. Based on the available literature, 
the ratio of quercetin to kaempferol to isorhamnetin 
should be 5:5:1 on average.
The indicator of particular relevance for unmasking 
possible counterfeiting is the quercetin to kaempferol 
(Q/K) ratio that should approximate 1, but can also 
fall within a somewhat wider range of 0.8-1.65.
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Given that the extract whose percent-share of fla-
vone glycosides has been deliberately adjusted by vir-
tue of quercetin addition comprises a due amount of 
flavone glycosides, the products harboring such an ex-
tract can be mistaken for genuine if controlled in an 
inappropriate manner. Therefore, unmasking the po-
tential fraud equally calls for appropriate choice of an 
analytical procedure and appropriate interpretation of 
the results obtained. Lately, the analyses of target 
products have ever more often revealed a substantially 
higher share of kaempferol in such preparations, sug-
gesting possible counterfeiting in terms of GBE re-
placement by an extract of the Chinese plant termed 
Sophora japonica L. (Fructus sophorae), which comprises 
ten-fold higher amounts of kaempferol than Ginkgo 
biloba L. However, apart from harboring high amounts 
of quercetin and kaempferol, the plant in reference 
also comprises a phytoestrogen falling into the group 
of isoflavones and termed genistein. The latter has a 
marked pharmacological activity and acts similar to 
estrogen hormones; therefore, its presence should be 
advertised on product labels. Due to an ever more fre-
quent use of the Sophora japonica L. extract as a re-
placement for GBE, analyses aiming at detecting the 
genistein presence in GBE-based products have been 
proposed, positive outcomes thereby being considered 
as counterfeiting markers.
Verification of genuineness and quality of GBE 
and GBE-based products relies on the analysis of its 
key components falling into the groups of flavonoids 
and terpene trilactones. The compounds most often 
determined within the frames of these analyses are 
ginkgo flavone glycosides, while terpene trilactones 
analyses, although important for comprehensive verifi-
cation of analyzed samples, are still less frequently rep-
resented in routine protocols.
The majority of techniques used for ginkgo flavone 
glycoside determination resort to high performance 
liquid chromatography (HPLC). Two most commonly 
implemented and internationally acknowledged tech-
niques are the technique stipulated under the Euro-
pean (and Croatian) Pharmacopoeia and the AOAC 
2006.07 technique.
The above techniques allow for determination of 
shares and mutual ratios of the three major flavonoids, 
that is, quercetin (Q), kaempferol (K) and isorhamne-
tin (I), the pertaining calculations thereby making use 
of conversion into their glycoside forms.
Given that products comprising the extract of the 
Ginkgo biloba L. plant are among the most often coun-
terfeited plant-based food supplements, it is of para-
mount importance to control these products using 
techniques that allow for establishment of individual 
representation and mutual ratios of the three substanc-
es listed above in a given product.
Controlling counterfeit products is as important 
today if not even more important than controlling the 
products and raw materials from secondary pollution 
as a consequence of inappropriate production or stor-
age and storage of raw materials, especially in connec-
tion with the increasing pollution of plant and prod-
ucts with different types of heavy metals35 or mycotox-
ins36 and possible adverse health effects.
Aim
This study aimed at verifying the quality, safety 
and accuracy of information labeled on GBEs and 
GBE-based food supplements available on the Croa-
tian market. The above parameters are essential for safe 
administration of these preparations and for gaining 
consumer trust, since only high-quality natural prod-
ucts comprising due shares of active substances are ca-
pable of achieving the anticipated and rightfully ex-
pected biological effects.
Within the frame of the study, 10 types of Ginkgo 
biloba L.-based products circulating on the market, in-
cluding two GBEs and eight food supplements (for-
mulated as capsules, tablets or powder) were analyzed 
in the laboratories of the Croatian Institute of Public 
Health. The study goal was to uncover the possible 
counterfeit drugs comprising ingredients potentially 
jeopardizing patient/consumer health or misleading 
the patients/consumers using them.
Materials and Methods
Representative samples of GBE-based products, de-
livered to the test laboratory in undamaged packaging 
and sampled to the effect of unmasking possible coun-
terfeiting, i.e. false labeling, were analyzed. In total, 10 
types of products were analyzed, including two GBEs 
and eight Ginkgo biloba L.-based food supplements.
To the above end, the AOAC 2006.07 technique6 
that relies on determination of shares of the flavone 
aglycones quercetin, kaempferol and isorhamnetin was 
used. The study made use of a Shimadzu HPLC sys-
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tem and the pertaining CLASS-VP Software, a Photo 
Diode Array detector and Supelcosil LC-18 (4.6x250 
mm) column, the mobile phase thereby being repre-
sented by 0.85%-phosphoric acid:methanol (1:1 v/v).
The total concentration of flavone glycosides was 
calculated as the sum of individual concentrations of 
three flavone glycosides at the 370 nm wavelength. 
Wavelength was modified to 270 nm because of better 
visibility L, as shown in all chromatograms. The purity 
of quercetin dihydrate (i.e. molecular water; 302/338= 
0.893), kaempferol and isorhamnetin [substance (mg) 
x purity = substance (mg)] was also taken into account. 
The obtained aglycone shares were then multiplied by 
the conversion factor used for calculation of the cor-
respondent glycoside forms.
Flavone glycosides of the three aglycones were es-
tablished as percent-shares of individual glycosides us-
ing either the equation:
% of an individual glycoside (% m/m) = (C x FV x 
F x 100)/W), where:
•	 C stands for the concentration of aglycones 
(mg/mL) calculated from the calibration curve;
•	 FV stands for the final volume;
•	 F stands for the aglycone conversion factor; and
•	 W stands for the mass proportion of the tested 
sample (mg);
or as individual glycosides comprised by a single cap-
sule or tablet using the equation:
2% of a given glycoside/tablet (mg) = ((C x FV x F 
x 100)/W) x T, where:
•	 C stands for the concentration of aglycones 
(mg/mL) calculated from the calibration curve;
•	 FV stands for the final volume;
•	 F stands for the aglycone conversion factor;
•	 W stands for mass proportion of the tested 
 sample (mg); and
•	 T stands for the average tablet/capsule mass (mg)
The following conversion factors were applied: 
quercetin, 2.504; kaempferol, 2.588; and isorhamnetin, 
2.437.
Results
Within the study frame, a total of 10 representative 
samples (2 GBEs and 8 food supplements) delivered 
to the test lab in undamaged packages were analyzed.
The GBE standard prepared from the reference 
substances in terms of quercetin, kaempferol and isor-
hamnetin was used for plotting a control chart based 
on which these aglycones, expressed in their glycoside 
forms, were identified in tested samples (Figs. 1-15).
Fig. 1. Chromatogram of the standard used for plotting  
a GBE flavonoid control chart.
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Sample No 1 – coated tablets; labeled information: 80 mg of GBE in two coated tablets; recommended 
 dosage: 1 coated tablet 2x/day
The total amount of ginkgo flavone glycosides constituting sample No 1, expressed per two coated tablets 
(i.e. per daily recommended dose) equaled 6.17 mg. The amount of GBE having 7% of ginkgo flavone glycosides 
(as advertised on the label) comprised by two coated tablets equaled 87.64 mg, while the quercetin/kaempferol 
ratio equaled 1.0.
The results displayed below also bring information on the quantity of each ginkgo flavone glycoside under 
study and on the pertaining measurement uncertainty, as follows:
quercetin = (3625±207) mg/kg K=3; confidence level: roughly 99% 
kaempferol = (3611±224) mg/kg K=3; confidence level: roughly 99% 
isorhamnetin = (479±90) mg/kg K=3; confidence level: roughly 99%
Fig. 2. Chromatogram of sample No 1.
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Sample No 2 – capsules, labeled information: 60 mg of GBE in a single capsule; recommended dosage: one 
capsule/day
The total amount of ginkgo flavone glycosides constituting sample No 2, comprised by a single capsule, 
equaled 14.52 mg, while the amount of GBE having 24% of ginkgo flavone glycosides (as advertised on the label) 
comprised by a single capsule equaled 60.5 mg, the quercetin/kaempferol ratio thereby being 1.03.
The results displayed below also bring information on the quantity of each ginkgo flavone glycoside under 
study and on the pertaining measurement uncertainty, as follows:
quercetin = (22802±1230) mg/kg K=3; confidence level: roughly 99%
kaempferol = (22174±1375) mg/kg K=3; confidence level: roughly 99%
isorhamnetin = (1858±349) mg/kg K=3; confidence level: roughly 99%
Fig. 3. Chromatogram of sample No 2.
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Sample No 3 – capsules; labeled information: 40 mg of GBE; recommended dosage: two tablets 1x/day
The total amount of ginkgo flavone glycosides constituting sample No 3, comprised by a single capsule, 
equaled 9.23 mg, while the amount of GBE having 24% of ginkgo flavone glycosides (as advertised on the label) 
equaled 380.5 mg, the quercetin/kaempferol ratio thereby being 1.17.
The results displayed below also bring information on the quantity of each ginkgo flavone glycoside under 
study and on the pertaining measurement uncertainty, as follows:
quercetin = (14117±805) mg/kg K=3; confidence level: roughly 99%
kaempferol = (12031±746) mg/kg K=3; confidence level: roughly 99%
isorhamnetin = (1827±343) mg/kg K=3; confidence level: roughly 99%
Fig. 4. Chromatogram of sample No 3.
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Sample No 4 – gelatine-coated capsules; labeled information: 60 mg of GBE in a single capsule; recom-
mended dosage: one capsule/day
The total amount of ginkgo flavone glycosides constituting sample No 4, comprised by a single gelatine-
coated capsule, equaled 14.03 mg, while the amount of GBE having 24% of ginkgo flavone glycosides (as adver-
tised on the label) comprised by a single gelatine-coated capsule equaled 58.4 mg, the quercetin/kaempferol ratio 
thereby being 1.04.
The results displayed below also bring information on the quantity of each ginkgo flavone glycoside under 
study and on the pertaining measurement uncertainty, as follows:
quercetin = (9460±539) mg/kg K=3; confidence level: roughly 99%
kaempferol = (9057±562) mg/kg K=3; confidence level: roughly 99%
isorhamnetin = (1520±286) mg/kg K=3; confidence level: roughly 99%
Fig. 5. Chromatogram of sample No 4.
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Sample No 5 – gelatine-coated capsules, labeled information: 60 mg of GBE in a single gelatine-coated 
capsule; recommended dosage: one capsule/day
The total amount of ginkgo flavone glycosides constituting sample No 5, comprised by a single gelatine-
coated capsule (660 mg), equaled 14.11 mg, while the amount of GBE having 24% of ginkgo flavone glycosides 
(as advertised on the label) comprised by a single gelatine-coated capsule equaled 58.80 mg, the quercetin/
kaempferol ratio thereby being 1.06.
The results displayed below also bring information on the quantity of each ginkgo flavone glycoside under 
study and on the pertaining measurement uncertainty, as follows:
quercetin = (9337±532) mg/kg K=3; confidence level: roughly 99%
kaempferol = (8402±521) mg/kg K=3; confidence level: roughly 99%
isorhamnetin = (1077±202) mg/kg K=3; confidence level: roughly 99%
Fig. 6. Chromatogram of sample No 5.
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Sample No 6 – coated tablets; labeled information: 80 mg in a single coated tablet; recommended dosage: 
one coated tablet/day
The total amount of ginkgo flavone glycosides comprised by two coated tablets equaled 5.78 mg, while the 
amount of GBE having 24% of ginkgo flavone glycosides (as advertised on the label) comprised by a single 
coated tablet equaled 82.6 mg, the quercetin/kaempferol ratio thereby being 0.99.
The results displayed below also bring information on the quantity of each ginkgo flavone glycoside under 
study and on the pertaining measurement uncertainty, as follows
quercetin = (3331±190) mg/kg K=3; confidence level: roughly 99%
kaempferol = (3363±208) mg/kg K=3; confidence level: roughly 99%
isorhamnetin = (680±128) mg/kg K=3; confidence level: roughly 99%
Fig. 7. Chromatogram of sample No 6.
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Sample No 7 – capsules; labeled information: 60 mg GBE in a single capsule; recommended daily dosage: 
one capsule
The total amount of ginkgo flavone glycosides comprised by a single capsule (660 mg) equaled 14.1 mg, while 
the amount of GBE having 24% of ginkgo flavone glycosides (as advertised on the label) comprised by a single 
capsule equaled 58.7 mg, the quercetin/kaempferol ratio thereby being 0.84.
The results displayed below also bring information on the quantity of each ginkgo flavone glycoside under 
study and on the pertaining measurement uncertainty, as follows:
quercetin = (9389±535) mg/kg K=3; confidence level: roughly 99%
kaempferol = (11196±694) mg/kg K=3; confidence level: roughly 99%
isorhamnetin = (745±140) mg/kg K=3; confidence level: roughly 99%
Fig. 8. Chromatogram of sample No 7.
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Sample No 8 – capsules; labeled information: 40 mg GBE in a single capsule; recommended daily dosage: 
one capsule
The total amount of ginkgo flavone glycosides constituting sample No 8, comprised by a single capsule (660 
mg), equaled 9.34 mg, while the amount of GBE having 24% of ginkgo flavone glycosides (as advertised on the 
label) comprised by a single capsule equaled 38.95 mg, the quercetin/kaempferol ratio thereby being 1.03.
The results displayed below also bring information on the quantity of each ginkgo flavone glycoside under 
study and on the pertaining measurement uncertainty, as follows:
quercetin = (21844±1245) mg/kg K=3; confidence level: roughly 99%
kaempferol = (21555±1318) mg/kg K=3; confidence level: roughly 99%
isorhamnetin = (3615±680) mg/kg K=3; confidence level: roughly 99%
Fig. 9. Chromatogram of sample No 8.
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Sample No 9 – dry Ginkgo biloba L. leaf extract
The established percent-share of ginkgo flavone glycosides equaled 23.3%, with the quercetin/kaempferol 
ratio of 1.09.
The results displayed below also bring information on the quantity of each ginkgo flavone glycoside under 
study and on the pertaining measurement uncertainty, as follows:
quercetin = (117255±6684) mg/kg K=3; confidence level: roughly 99%
kaempferol = (107279±6651) mg/kg K=3; confidence level: roughly 99%
isorhamnetin = (8483±1595) mg/kg K=3; confidence level: roughly 99%
Fig. 10. Chromatogram of sample No 9.
Maja Budeč et al. Verification of authenticity of Ginkgo biloba L. leaf extract
686 Acta Clin Croat, Vol. 58, No. 4, 2019
Sample No 10 – dry Ginkgo biloba L. leaf extract
The established percent-share of ginkgo flavone glycosides equaled 25.52%, with the quercetin/kaempferol 
ratio of 0.83.
The results displayed below also bring information on the quantity of each ginkgo flavone glycoside under 
study and on the pertaining measurement uncertainty, as follows:
quercetin = (112448±6410) mg/kg K=3; confidence level: roughly 99%
kaempferol = (135030±8372) mg/kg K=3; confidence level: roughly 99%
isorhamnetin = (7708±1449) mg/kg K=3; confidence level: roughly 99%
Fig. 11. Chromatogram of sample No 10.
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Fig. 12. Chromatogram of the reference genistein standard.
Fig. 13. Chromatogram of sample No 7 with a visible genistein peak.
Based on the results obtained and chromatograms 
of the 10 samples analyzed, it was concluded that the 
samples No 1, 2, 3, 4, 5, 6, 8 and 9 fully complied with 
the labeled information on the total amount of ginkgo 
flavone glycosides and their mutual ratios.
However, the quercetin to kaempferol ratios estab-
lished in samples No 7 and No 10 (0.83 and 0.84, re-
spectively) were at the lower limit as compared with 
the Q/K reference values published for the standard-
ized Ginkgo biloba L. leaf extract in the literature 
sources (0.8-1.65). In both samples, there also was an 
unusual peak not seen on chromatographs descriptive 
of other samples. The assumption that the peak in 
question arose due to the presence of genistein was 
confirmed by virtue of additional analyses made by use 
of the genistein standard.
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Fig. 14. Chromatogram of sample No 10 with a visible genistein peak.
Fig. 15. Chromatogram of a valid genistein-free sample.
Even though both samples conformed to the la-
beled information on the established GBE quantity 
calculated based on the established quantity of ginkgo 
flavone glycosides, suspicion of their safety arose as 
soon as kaempferol concentrations markedly higher 
than those of quercetin (Q/K: 0.84 and 0.83, respec-
tively) were established. The documented peak atypical 
of GBE, identified as a phytoestrogen falling into the 
group of isoflavones, that is, genistein, was an addi-
tional indication of possible counterfeiting of ginkgo 
extract in the target samples by virtue of Fructus sopho-
rae (Sophora japonica L.) extract addition.
Discussion
According to the reports submitted by sanitary in-
spections, GBE counterfeiting has been witnessed not 
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only in Croatia, but also in other EU member states; 
even more so, Ginkgo biloba L.-based products fall into 
the category of most often counterfeited food supple-
ments of herbal origin.
The results of this study showed the quercetin/
kaempferol ratio (of 0.84) out of the ordinary for stan-
dardized GBE-based products and reaching the lower 
limit of the ratio span quoted in the reference litera-
ture (0.8-1.65) to be established in 20% of the samples 
analyzed. Analysis of the HPLC chromatograms re-
vealed the results to be indicative of counterfeiting; 
judging by the results obtained, in the products in ref-
erence, GBE was substituted with a cheaper Sophora 
japonica L. extract, thereby misleading the consumers 
that ultimately failed to achieve the therapeutic effect 
expected to be achieved should a genuine GBE be 
consumed. Due to its acting mechanisms that mimic 
those of estrogen hormones, the presence of genistein, 
i.e. a phytoestrogen falling into the group of isofla-
vones, could result in adverse pharmacological effects 
in some consumer groups; therefore, the presence of 
genistein should unanimously be advertised on the 
products containing it.
This study confirmed the importance of continuous 
control of products containing the Ginkgo biloba L. 
plant extract. This control should make use of a stan-
dardized technique and proper interpretation of its 
results. The technique chosen to be employed to the 
above effect should allow not only for determination 
of shares of the three major ginkgo flavone glycosides, 
but also determination of their mutual ratios; other-
wise, an invalid sample might be adjudicated as valid. 
Namely, should the analysis be boiled down solely to 
determination of the three major flavone glycosides, 
the possible substitution of GBE with a certain 
amount of plant extract of other origin but similar fla-
vonoid composition, or possible spiking of the prepa-
ration with quercetin not originating from the Ginkgo 
biloba L. might go under the radar, since the total 
amount of ginkgo flavone glycosides contained by 
counterfeit drugs most often complies with the labeled 
amount.
Because of their marked biological activity and 
profound influence on human health, prior to their 
marketing authorization, the products containing 
Ginkgo biloba L. should be registered with and ap-
proved by the Ministry of Health. The issue here is the 
fact that once authorized for sale, a product usually 
ceases to be a subject of quality control, which makes 
the trueness of the label statements dubious, and might 
compromise the expected health effects and misguide 
consumers.
Of note, comparison of the results of our study 
with the results of the monitoring program launched 
by the Ministry of Health and carried out under the 
roof of the Croatian Public Health Institute in 2008, 
during the course of which over 76% of the samples 
analyzed were unmasked as invalid (as regards the to-
tal amount of GBE and/or quercetin/kaempferol ra-
tio), revealed that, since then, counterfeiting of Ginkgo 
biloba L.-based products in the Republic of Croatia 
has decreased in frequency by almost 50%. By all 
means, this favorable trend comes as a result of two 
additional monitoring programs launched by the Min-
istry of Health in the last seven years, as well as of the 
activities of competent authorities taken post monitor-
ing, which resulted in mandatory withdrawal of invalid 
products from the market, their market re-release be-
ing granted solely provided that their formulation has 
been duly corrected in terms of adding a genuine GBE, 
as corroborated by subsequent analysis of the corrected 
products.
Conclusions
The results of the analysis of ginkgo flavone glyco-
sides in the products comprising the Ginkgo biloba L. 
plant extract, marketed in the form of food supple-
ments and pure GBE-based products, revealed 20% of 
the samples to be counterfeited, meaning that their 
actual composition did not comply with the composi-
tion advertised on the label, which could easily deceive 
potential consumers. The extract of the Sophora japon-
ica L. plant, found in two counterfeit products, does 
not act in the same pharmacological manner as does 
the Ginkgo biloba L. extract declared as present in these 
preparations, due to which the users of the counterfeit 
drugs failed to benefit from the expected pharmaco-
logical effects. A false label that intentionally neglects 
to inform consumers about the presence of the Sophora 
japonica L. extract actually deprives them of the infor-
mation on the presence of pharmacologically active 
genistein, a phytoestrogen which, due to the similarity 
of its acting mechanisms with those of estrogen hor-
mones, might exhibit adverse effects in some consumer 
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groups and should therefore always be clearly declared 
as present in any product comprising it.
Beneficial effects of Ginkgo biloba L. ingredients in 
terms of human health preservation and improvement 
can be achieved solely by virtue of administration of 
authentic and standardized plant extracts. The ever-
increasing presence of counterfeit drugs on the global 
market can be decreased only through continuous con-
trol of safety and appropriateness of the marketed 
products. Analytical techniques employed to this end 
should be reliable and acknowledged, while the final 
product safety report should inform not only on the 
total amount of ginkgo flavone glycosides, but also on 
their mutual ratios, and should provide solid evidence 
for GBE genuineness.
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Sažetak
PROVJERA AUTENTIČNOSTI EKSTRAKTA LISTA BILJKE GINKGO BILOBA L. I PROIZVODA  
KOJI GA SADRŽE NA HRVATSKOM TRŽIŠTU PUTEM ANALIZE KOLIČINE I OMJERA  
GINKOFLAVONOGLIKOZIDA (KVERCETIN, KEMPFEROL I IZORAMNETIN) I TERPENSKIH  
TRILAKTONA U SVRHU OTKRIVANJA KROVOTVORENIH PRIPRAVAKA OPASNIH  
ZA ZDRAVLJE KORISNIKA
M. Budeč, J. Bošnir, A. Racz, D. Lasić, D. Brkić, A. Mosović Ćuić, Ž. Kuharić, G. Jurak i L. Barušić
Ginkgo biloba L. najstarija je biljka na zemlji, a pripravci od njegovih listova i sjemenaka dio su kineske medicine već više 
tisuća godina. Vrstu je 1771. godine otkrio Linnaeus, a ime je dobila od latinskih riječi bis, tj. dva i lobus zbog specifičnog 
oblika lista. Današnji farmaceutski oblici biljke Ginkgo biloba L. sadrže uglavnom ekstrakte iz listova ubranih ujesen kada je 
najveća koncentracija aktivnih komponenata. Suvremenim istraživanjima određen je kemijski sastav njegovog lista, a utvrđe-
ni su i mehanizmi njegovog pozitivnog djelovanja na reološka svojstva krvi i ubrzanje njezinog protoka. Visoka cijena i veli-
ka popularnost ubrzo su postali poticaj za krivotvorenje ekstrakta biljke Ginkgo biloba L. jeftinijim ekstraktima drugih biljaka. 
Naime, suvremeni medicinski proizvodi i dodaci prehrani na osnovi biljke Ginkgo biloba L. sadrže ekstrakte njegovog lista 
koji se standardiziraju prema njegovim ključnim farmakološki aktivnim sastavnicama; najčešće je to 22%-27% flavonoid 
glikozida i 6%-7% terpenskih trilaktona. Kvercetin, kempferol i izoramnetin su dominantni i farmakološki najvažniji flavo-
noidi, a njihova ukupna količina i međusobni omjeri nedvojben su pokazatelj autentičnosti ekstrakta. Stoga se i većina ana-
liza za utvrđivanje ispravnosti proizvoda koji sadrže biljku Ginkgo biloba L. temelji na analizi ovih parametara. Krivotvorenja 
podrazumijevaju djelomičnu ili potpunu zamjenu ektrakta Ginkgo biloba L. nekim jeftinijim biljnim ekstraktom sličnog 
 sastava uz eventualno obogaćivanje dodatnom količinom flavonoida, najčešće kvercetina, koji ne potječu od biljke Ginkgo 
biloba L. Svrha ovoga rada bila je provjeriti autentičnost i kakvoću pripravaka Ginkgo biloba L. na hrvatskom tržištu. Anali-
zirano je ukupno 10 uzoraka različitih proizvođača. Kao pokazatelji njihove ispravnosti određivani su udjeli aglikona karak-
terističnih ginkoflavonoglikozida: kvercetin, kempferol i izoramnetin te omjeri nađenih količina kvercetina i kempferola kao 
ključni pokazatelji krivotvorenja ginkgo-ekstrakta. Količina ginkoflavonoglikozida određena je metodom tekućinske kroma-
tografije visoke djelotvornosti. Analizom je utvrđeno da 80% uzoraka odgovara navodima deklaracije u pogledu ukupne 
 količine flavonoglikozida kao i u pogledu njihovog međusobnog omjera. U 20% uzoraka omjer kvercetina i kempferola od-
stupao je od uobičajenih vrijednosti, a dokazano je i prisustvo fitoestrogena genisteina, jedne od karakterističnih sastavnica 
biljke Sophora japonica L., čijim ekstraktom je krivotvoren ginkgo-ekstrakt u analiziranim uzorcima. Zbog neistinite dekla-
racije na proizvodima koji su sadržavali ove ekstrakte izostalo je i obvezno upozorenje o prisutnosti farmakološki aktivnog 
genisteina koji može izazvati neželjene zdravstvene posljedice kod pojedinih skupina potrošača. Rezultati ovoga rada uka zuju 
na značajnu pojavnost krivotvorenja proizvoda biljke Ginkgo biloba L. na hrvatskom tržištu te se zbog toga predlaže njihova 
temeljitija kontrola kao i sankcioniranje neodgovornih proizvođača i trgovaca, čime bi se doprinijelo većem udjelu kvalitet-
nijih proizvoda i izbjegli zdravstveni rizici te smanjila pojavnost prijevare.
Ključne riječi: Ginkgo biloba; Kvercetin; Krivotvoreni lijekovi; Hrvatska
